

**A GUIDE TO  
BIOTECHNOLOGY LAW  
AND BUSINESS**



**A GUIDE TO  
BIOTECHNOLOGY LAW  
AND BUSINESS**

**Robert A. Bohrer**

CALIFORNIA WESTERN SCHOOL OF LAW

CAROLINA ACADEMIC PRESS

---

Durham, North Carolina

Copyright © 2007  
Robert A. Bohrer  
All Rights Reserved.

Library of Congress Cataloging-in-Publication Data

Bohrer, Robert A.

A guide to biotechnology law and business / by Robert A. Bohrer.  
p. cm.

Includes bibliographical references and index.

ISBN-13: 978-1-59460-087-6 (alk. paper)

ISBN-10: 1-59460-087-2 (alk. paper)

1. Biotechnology industries--Law and legislation--United States.
2. Biotechnology--Law and legislation--United States. I. Title.

KF3133.B56B64 2007  
343.73'0786606--dc22

2007005410

Carolina Academic Press  
700 Kent Street  
Durham, North Carolina 27701  
Telephone (919) 489-7486  
Fax (919) 493-5668  
www.cap-press.com

Printed in the United States of America.

*For My Parents  
Ira Bohrer of Blessed Memory  
and Charlotte Bohrer  
Who Shared Their Love of Learning With Me*

*And*

*To the Memory of Vince Frank,  
Who Would Have Coauthored This Book*



# CONTENTS

Table of Cases	xvii
Acknowledgments	xix
<b>Chapter 1 An Introduction to Biotechnology Law and Business</b>	<b>3</b>
§1.0 Biotechnology: Infinite Promise and Infinitely Challenging	3
§1.1 The Purpose of This Book	4
§1.1(A) An Overview of This Book	4
§1.2 What is Biotechnology?	5
§1.2(A) The Scope of the Biotechnology Industry	6
§1.2(B) Applications of Biotechnology: Human Health	7
§1.2(B)(1) Human Therapeutics	8
§1.2(B)(2) Diagnostics for Human Disease	11
§1.2(B)(3) Vaccines	12
§1.2(C) Applications of Biotechnology: Agriculture	12
§1.2(D) Industrial Applications of Biotechnology	13
§1.3 Summary: The Life Cycle of Biotechnology and the Lawyer's Role	14
<b>Chapter 2 A Primer on the Basic Science and Applications of Biotechnology</b>	<b>19</b>
§2.0 Modern Molecular Biology and Immunology	19
§2.1 DNA and the Genetic Code	19
§2.1(A) From DNA to RNA to Protein: The Central Dogma of Molecular Biology (Now Known to be False!)	20
§2.1(B) Genes: The Recipe for a Protein	21
§2.1(C) Genes, Proteins, and Splice Variants	21
§2.1(D) Putting It All Together: Genomes, Genotypes, and Phenotypes	22
§2.2 Prokaryotes, Eukaryotes, and Viruses	23
§2.2(A) Viruses	24
§2.2(B) Bacteria (Prokaryotes)	24

§2.2(C) Eukaryotes	25
§2.3 Introductory Genetic Engineering for Beginning Non-Biologists	25
§2.3(A) Gel Electrophoresis	26
§2.3(B) DNA Sequencing	27
§2.3(C) Cloning Genes	28
§2.3(D) Polymerase Chain Reaction	29
§2.4 An Introduction to Immunology (and Monoclonal Antibodies)	29
§2.5 Applications of Genetic Engineering in Health Care	34
§2.5(A) Genetically Engineered Vaccines	34
§2.5(B) Diagnostic Gene Probes	35
§2.5(C) Therapeutic Applications of Genetic Engineering	36
§2.5(D) Genetic Engineering and Human Gene Therapy	38
§2.6 Applications of Monoclonal Antibody Technology in Health Care	40
§2.6(A) Therapeutic Uses of Monoclonal Antibodies	41
§2.7 Genetic Engineering Applications in Agriculture and Industry	42
§2.8 Summary	43
<b>Chapter 3 Technology Transfer: The University-Industry Connection</b>	<b>45</b>
§3.0 Introduction: Universities and Research Institutes—Where Biotechnology Is Born	45
§3.1 An Introduction to the Bayh-Dole Act: Transfer of Technology Developed with Federal Research Funding	46
§3.2 The Requirements of Bayh-Dole for Universities	48
§3.2(A) Assignment of Rights	48
§3.2(B) Sharing Proceeds	50
§3.3 The University Office of Technology Transfer (OTT): Functions and Models	51
§3.3(A) Disclosure	51
§3.3(B) Evaluation	52
§3.3(C) Marketing	53
§3.3(D) Licensing	55
§3.3(E) Monitoring and Enforcement	55
§3.4 Alternative Models of Technology Transfer: Scripps, the NIH Guidelines, and Post-NIH Guidelines Developments	56
§3.4(A) The Scripps Research Institute (TSRI) Significant Relationship Model	56
§3.4(B) The NIH Guidelines: Developing Sponsored Research Agreements: Considerations for Recipients of NIH	



Research Grants (59 FR 32997-02, Monday, June 27, 1994) (“NIH Sponsored Research Guidelines”)	58
§3.5 Licensing a University Invention (Also a Few Tips on Negotiation)	60
§3.5(A) Licensed Technology	62
§3.5(B) Sublicensing	63
§3.5(C) Field of Use, Geographic Territory, and Exclusive Versus Non-Exclusive	64
§3.5(D) Royalties, Licensing Fees, and Milestone Payments	66
§3.5(E) The Bottom Line on University Licensing	67
§3.6 Sponsored Research Agreements	67
§3.6(A) The Description of the Research	67
§3.6(B) Time for Review before Publication	68
§3.6(C) Sponsor’s Rights to Inventions Resulting from the Sponsored Research	68
§3.7 Conclusion: University Technology and Biotechnology	69
<b>Chapter 4 Intellectual Property (IP) Protection for Biotechnology</b>	<b>71</b>
§4.0 Introduction: The Need for Patents and the Patentability of Biotechnology	71
§4.1 Patents and Trade Secrets: Choosing a Method for Protection	73
§4.2 Differences Between U.S. and Foreign Patent Law	75
§4.3 Patentable Subject Matter	77
§4.4 New and Useful: The Requirement of Utility	80
§4.5 Novelty and Publication	82
§4.6 Nonobviousness	84
§4.6(A) Secondary Evidence of Nonobviousness	88
§4.7 Written Description, Enablement, and Best Mode: The Requirements of §112	89
§4.8 Other Special Problems for Biotechnology Patents	93
§4.8(A) Protection from Foreign Competition	93
§4.8(B) Biotechnology Products Derived from Human Tissue	95
§4.8(C) Patent Protection for Stem Cell Research and Development	96
§4.9 Biotechnology Patents: Moral and Ethical Issues	97
§4.9(A) The Rights of Indigenous Peoples	97
§4.9(B) Patent Protection for Drugs Derived from Traditional Remedies	99

§4.9(C) Patenting Animals: Beyond Patentable Subject Matter to Agricultural Policy and Animal Rights	99
§4.10 Broad Patent Claims to Drug Targets	100
§4.11 Patent Infringement and the Doctrine of Equivalents	102
§4.11(A) Reverse Equivalents	104
§4.11(B) Unexpected Results	105
§4.12 Conclusion: Future Directions for Biotechnology Patent Law	105
§4.12(A) International Patent Issues	106
§4.12(B) Life-Saving Pharmaceuticals in Developing Countries	106
§4.12(C) Scientific Progress, the Human Genome Initiative, and Changes in Patent Law	106
<b>Chapter 5 Biotechnology Business Strategy</b>	<b>109</b>
§5.0 Introduction (Including a Brief History of Biotech Business Models)	109
§5.1 Strategic Planning for the New “Hybrid” Biotechnology	112
§5.1(A) The Role of Markets in Strategic Planning	113
§5.1(B) Minimizing Risk in Clinical Development: Animal Models, Clinical Trial Costs (Sizes and Duration), Clear Pathways, and Unmet Medical Needs	115
§5.2 Integrating Regulatory Strategy and Market Issues	119
§5.3 Financing Biopharmaceutical Development: Considerations and Strategy	120
§5.4 Summary: The Multiple Strands of a Biotech Business Plan	125
<b>Chapter 6 Financing the Process of Development</b>	<b>129</b>
§6.0 Introduction	129
§6.1 A Brief Introduction to Corporations and Securities: (The MBAs and Lawyers May Wish to Skip This Section)	130
§6.2 Selling Securities: Caveat Vendor	132
§6.3 In the Beginning: Is There an Angel in the House?	132
§6.4 Venture Capital Financing Issues	134
§6.4(A) Due Diligence	135
§6.4(B) Valuation of the Investment (and the Company)	137
§6.4(C) Capital Structure: Authorized Shares	139
§6.4(D) Stock Options Plans	140
§6.4(E) Stages of Venture Capital Investment	141
§6.4(F) Anti-Dilution	142

§6.5 Beyond the First Round: Licensing and Corporate Strategic Alliances	142
§6.5(A) The Framework for a Strategic Alliance	144
§6.5(B) Timing of Alliances and the Impact on Valuation	145
§6.5(C) Foreign Partnerships	148
§6.6 Introduction to the Public Offering	149
§6.6(A) The Decision to Go Public	149
§6.6(B) Preparing the Public Offering: The Letter of Intent	151
§6.6(C) Going Public: The Team	151
§6.6(D) Going Public: Due Diligence	152
§6.6(E) Going Public: Filing the Registration Statement	153
§6.6(F) Going Public: The Effective Date and the Closing Date	154
§6.6(G) Going Public: The Quiet Period	155
§6.6(H) Going Public: Lock-Up Periods and the PSLRA “Safe Harbor”	156
§6.7 Conclusion: Biotechnology Finance as a Four-Dimensional Rubik’s Cube	158
<b>Chapter 7 An Overview of the Regulation of Biotechnology</b>	<b>161</b>
§7.0 Introduction	161
§7.1 History of the Regulation of Genetic Engineering	163
§7.2 Regulation Under the NIH Recombinant DNA Advisory Committee Guidelines (NIH-RAC)	164
§7.3 The FDA and Human Health Care Applications of Biotechnology	168
§7.3(A) The FDA Approval of Human Therapeutics and Diagnostics	168
§7.3(B) The FDA and New Animal Drugs	171
§7.4 The EPA and Agricultural Biotechnology	172
§7.4(A) EPA’s FIFRA Procedures for Field Testing Genetically Engineered Organisms	173
§7.4(B) The FIFRA Standard for the Approval of Pesticides	174
§7.5 EPA’S Regulation of Non-Agricultural Biotechnology—TSCA	175
§7.5(A) TSCA’s Scope, Procedures, and Standards	176
§7.5(B) Requirement of a Premanufacture Notice (PMN)	177
§7.6 The USDA and Agricultural Biotechnology	178
§7.6(A) USDA’s Regulation of Veterinary Biological Products—VSTA	179

§7.6(B) USDA’s Regulation of Genetically Engineered Microorganisms and Plants—PPA	181
§7.6(C) The Scope, Standards, and Procedures of the PPA	182
§7.7 The Regulation of Food Products from Genetically Engineered Plants	183
§7.7(A) Adulterated: The First Concept of Food Safety	183
§7.7(B) Food Additive: Added Substances That Do Not Adulterate	184
§7.7(C) Generally Recognized as Safe (Between Additive and Adulteration)	185
§7.7(D) Foods Derived from New Plant Varieties Created by Genetic Engineering—the FDA Statement of Policy	187
§7.7(E) Food Plants Engineered to Produce a Biopesticide or Treated with a Biotechnology Derived Biopesticide	192
§7.7(F) Conclusion: Risk Perception and Food Biotechnology	193
<b>Chapter 8 Special Regulatory Issues—FDA Regulation of Drugs,     Biologics, and Devices</b>	<b>197</b>
§8.0 Introduction	197
§8.1 Regulatory Strategy: An Introductory Example	199
§8.2 The FDA Structure and Statutory Authority for Drugs and Biologics (With a Brief Word about Devices)	200
§8.2(A) A Brief Excursion into the Distinction between Drugs and Biologics	201
§8.2(B) A Brief Word about Devices	205
§8.3 Stages of Drug Development and Drug Development Strategy	206
§8.3(A) From Preclinical Decision Making to NDA	209
§8.3(A)(1) The Five Key Parameters of Strategic Success: FDA Approval	210
§8.3(A)(2) Optimal Indication	210
§8.3(A)(3) The Shortest Possible Time	210
§8.3(A)(4) Conserving Scarce Resources: Time and Money	210
§8.3(A)(5) Planning for Reimbursement	211
§8.3(B) Strategic Issues in the Development Process and the Terms of Success	211
§8.3(B)(1) The Preclinical Development Process and the Optimal Indication	212
§8.3(B)(2) Conserving Time and Money	214
§8.3(B)(3) Planning for Reimbursement	216

§8.3(C) Drug Development Strategy: Learning from the Mistakes of Previous Companies	216
§8.3(D) Conclusion: Planning the Clinical Development of a New Therapeutic Begins at the Early Preclinical Stage	220
§8.4 A Practical Guide to Clinical Trials and the NDA	220
§8.4(A) The New Drug Application or Product License Application	222
§8.4(B) Beyond Approval: Post-Marketing Issues	225
§8.4(C) Reporting Adverse Drug Experiences (ADEs)	226
§8.5 Accelerated Approval and Early Access to Unapproved Drugs: Drugs for Severely Debilitating and Life Threatening Illnesses	227
§8.5(A) Fast Track, Accelerated Approval, and Priority Review	227
§8.5(B) Early Access to Experimental Drugs	229
§8.6 Product Exclusivity and the FDA: Orphan Drugs, Patent Term Extension, and Pediatric Study Extensions	231
§8.6(A) The Orphan Drug Act	231
§8.6(B) Patent Term Restoration	233
§8.6(C) Pediatric Study Patent Extensions	235
§8.7 “Generic Biopharmaceuticals”	237
§8.8 Advertising and Promoting Prescription Drugs (Herein Also a Brief Word about Dietary Supplements-DSHEA)	241
§8.8(A) The Legal Background of the FDA’s Marketing and Promotion Regulation	241
§8.8(B) Marketing to Physicians and Formulary Committees	243
§8.8(C) Direct-to-Consumer (DTC) Advertising in Print and by Electronic Media	245
§8.9 DSHEA—Anything Goes (Almost)	247
§8.10 Postscript: International Pharmaceutical Regulation and Harmonization	253
<b>Chapter 9 Ethical Perspectives on New Ethical Dilemmas for Biotechnology</b>	<b>257</b>
§9.0 Introduction	257
§9.1 The Scientific Advances and Ethical Challenges to Biotechnology Research and Development	258
§9.2 Ethical Frameworks and <i>A Theory of Justice</i>	260
§9.3 Applying the Frameworks to the Problems	263
§9.3(A) Bioterrorism and Restraints on Research and Publication	263

§9.3(B) Balancing Incentives for Pharmaceutical Innovation against Affordability and Access for Persons with Medical Needs	265
§9.3(C) Echazabal and Workplace Genetic Testing: The Law and Ethics of Protecting Workers against Risks	266
§9.3(C)(1) The Legality of Protecting Workers against Risks to Their Own Health	267
§9.3(C)(2) <i>A Theory of Justice</i> and Workplace Genetic Testing	269
§9.4 Embryonic Stem Cell Research	274
<b>Chapter 10 Special Regulatory Issues: Human Gene Therapy</b>	<b>277</b>
§10.0 Introduction to Gene Therapy: At the Edge of a New Era in Medicine	277
§10.1 What is Gene Therapy?	278
§10.1(A) Candidate Diseases for Gene Therapy	280
§10.1(B) Selecting Appropriate Target Cells	281
§10.1(C) Methods for Delivering Therapeutic Genetic Material	281
§10.2 Risks of Gene Therapy	284
§10.2(A) The Risk of Producing Replication-Competent Viruses	285
§10.2(B) The Pathogenicity of Viral Vectors	286
§10.2(C) Summary: Risks of Gene Therapy	288
§10.3 The Regulatory Framework for Gene Therapy	289
§10.3(A) Notification of the NIH-RAC	289
§10.3(B) Appendix M and the NIH's Principal Concerns	290
§10.3(C) FDA Review of Gene Therapy Protocols	291
§10.4 The Ethical Debate over Gene Therapy	292
§10.4(A) General Limitations on Somatic Cell Gene Therapy	293
§10.4(B) Ethical Issues Surrounding Germ-Line Gene Therapy	294
§10.4(C) The Ethical Problem of Access to Gene Therapy	297
§10.5 Conclusion	298
<b>Chapter 11 Liability for Biotechnology Products</b>	<b>299</b>
§11.0 Introduction	299
§11.1 A Basic Overview of Negligence	300
§11.1(A) Violation of a Statute or Regulation as Negligence <i>Per Se</i>	301
§11.1(B) The Relevance of Custom to Negligence	302
§11.1(C) General Evidence of Reasonable Care	303
§11.2 An Introduction to Strict Product Liability	304

§11.2(A) Defective Condition Unreasonably Dangerous	305
§11.2(B) Manufacturing Defect	305
§11.2(C) Design Defect	306
§11.2(D) Failure to Warn	308
§11.2(E) Preemption of Liability by FDA Approval: A Complicated Tale	309
§11.3 Legal Cause: A Problem in Both Negligence and Strict Liability	311
§11.3(A) Expert Testimony in Product Liability Cases	312
§11.4 The National Vaccine Injury Compensation Program: 42 U.S.C. §300aa-1 <i>et seq.</i> (2006): One Answer to the Causation Conundrum	315
§11.5 Drugs, Vaccines, and Other Human Therapeutics as Unavoidably Unsafe: Restatement (Second) of Torts §402A Comment k	318
§11.6 Restatement of Torts (Third) and Product Liability Reform	320
§11.7 Liability for Biotechnology in Other Contexts: Beyond Product Liability for Drugs, Vaccines, and Medical Devices	322
§11.7(A) Liability in the Workplace	322
§11.7(B) Liability for Biotechnology Pesticides	327
§11.7(C) Liability for Food Products Produced by Biotechnology	328
§11.7(D) Liability for Other Biotechnology Products in Industry and the Environment	331
§11.8 Conclusion	332
Index	333





# TABLE OF CASES

- “Agent Orange” Product Liability  
Litigation, 312
- Amgen v. Chugai, 93
- Andrulonis v. U.S., 322
- Ariad Pharms., Inc. v. Eli Lilly & Co., 101
- Bates v. Dow Agrosiences, 327
- Brown v. Superior Court, 308, 332
- Burr v. Duryee, 102
- Chevron USA, Inc. v. Echazabal, 267
- Daubert v. Merrell Dow Pharmaceuticals,  
Inc., 313
- Diamond v. Chakrabarty, 46, 73
- Enzo Biochem v. GenProbe, 90
- Escola v. Coca-Cola Bottling Co. of  
Fresno, 305
- Festo Corp. v. Shoketsu Kinzoku Kogyo  
Kabushiki Co., 103
- Frye v. United States, 311
- Genentech, Inc. v. Wellcome Found. Ltd.,  
F.3d 1555 (Fed. Cir. 1994), 87
- Graham v. John Deere Co., 88
- Graver Tank, 102, 104
- Harvard College v. Canada, 78
- Hilton Davis Chem. Co. v. Warner Jenk-  
inson Co, Inc., 103
- Hormone Research Foundation, Inc. v.  
Genentech, 102
- Hybritech Inc. v. Monoclonal Antibodies  
Inc., 88
- In Re Allen, 77
- In re Bergy, 79
- In re Dillon, 919 F.2d 688 at 692, 105
- In re Graeme I. Bell, 85
- In re Hogan, 104–105
- In re Mayne, 105
- In re Thomas F. Deuel, 85
- Johns Hopkins v. Cellpro, 92
- Jurgens v. McKasy, 102
- Loctite Corp v. Ultraseal Ltd., 102
- Medtronic Inc., v. Lohr, 310
- Mexicali Rose v. Superior Ct., 329
- Moore v. Regents of University of  
California, 95
- NVE Inc. v. Thompson, 436 F.3d 182 (3rd  
Cir. 2006), 252
- Papas v. Upjohn, 327
- Parke Davis & Co. v. H.K. Mulford & Co.,  
72
- Penwalt Corp. v. Durand-Wayland Inc.,  
104
- Pharmanex v. Shalala, 221 F.3d 1151  
(10th Cir. 2000), 250
- Platzer v. Sloan-Kettering, 50
- Richardson v. Richardson-Merrell, 312
- Sanitary Refrigerator, 102
- Scripps Clinic & Research Found. v.  
Genentech Inc., 104
- The T.J. Hooper, 303
- Thompson v. Western States Medical  
Center, 535 U.S. 357 (2002), 242
- Warner-Jenkinson Co., Inc. v. Hilton  
Davis Chem. Co., 103
- Washington Legal Foundation v. Henney,  
202 F.3d 331, (D.C. Cir. 2000),  
242
- Yong Cha Hong v. Marriot Corp., 329



# ACKNOWLEDGMENTS

A great many people have helped me with this book in different ways. There are too many to list them all, but I shall list several in different categories.

First are those who specifically lent their time to reading drafts of this book and offering helpful suggestions. These include John Mendeloff of the University of Pittsburgh; Dale Busch, former General Counsel of the Salk Institute for Biological Studies; Jasmin Patel of Novartis; Jacob Handy of Morrison and Foerster; and, my wife Karen.

Second, there are many scientists who have contributed to my efforts to understand the science of biotechnology. These include the late Clifford Grobstein, of the University of California, San Diego (UCSD), who was my first guide to the field of biotechnology policy; Don Helinski, of UCSD, who gave me the opportunity to work and learn at UCSD's Center for Molecular Genetics; Ron Brown, a cofounder of Syntro and former CEO of Octamer, Inc., who first introduced me to the extraordinary world of biotechnology as a business; and, the late John O'Brien, of UCSD, who extended to me the great privilege of working with him for several years in the development and commercialization of his science. Mario Bourdon of the La Jolla Institute for Molecular Medicine provided me with the opportunity to learn about the world of non-profit biomedical research during my years as a member of the Board of that Institute. Ami Loewenstein of Technion's Dimotech and the faculties of Medicine and Biology at the Technion-Israel Institute of Technology in Haifa also were very generous in allowing me to work and learn about their science, research, and efforts in technology transfer

Third, there are those who have helped me develop as a lawyer and legal scholar. John Cribbet, the former Dean of the University of Illinois College of Law, strove to impart the importance of "the big picture" to generations of law students. Dean Cribbet, credit for my effort to see the big picture in this book is yours. The late Dean Albert Sachs, of Harvard Law School, helped me understand the value of legal scholarship. My colleague John Noyes has been

a sounding board for my ideas for over twenty years. Dean Steven Smith of California Western School of Law has encouraged me in all of my scholarship and particularly in my efforts to complete this book.

I have been very fortunate to teach Biotechnology Law to many wonderful students over the past decade or so and I owe much to them for their contributions to my class, which have helped expand my understanding of the issues and my efforts to communicate both technical and legal material. To name just a few I would mention: Lisa Haile of DLA Piper Rudnick Gray Cary; Christine Gritzmacher of GenProbe; Chris Dayton of BiogenIdec; Jayshree Gerken of Fish and Richardson, and, Rena Patel of Bristol Meyers Squibb.

My sons Matthew and Nathaniel have been very patient and supportive during the many hours I was working on this book that I otherwise would have spent with them. Biotechnology is about the science of life. You have taught me about its meaning.

I owe more than I can say to my Editor-For-Life and wife, Karen Bohrer, without whose help and support I could never have finished this project.

Thanks.

Bob Bohrer  
San Diego, California  
August 2006